Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Nitrogen-containing bisphosphonates have been associated with the development of osteonecrosis of the jaws (ONJ), but the lack of reliable epidemiological data and appropriate animal models has restricted our understanding of ONJ pathophysiology and limited its management. The best available information is from histopathologic findings, which implicate bone necrosis and infection, although it is not clear which is primary. However, there are data suggesting that macrophages could well be the central factor in allowing the infection to develop first, followed by local necrosis, which could also account for the development of ONJ in patients treated with denosumab, a human monoclonal antibody to the receptor activator of nuclear factor-κB ligand. This review examines the evidence that macrophages could play a prominent role in development of ONJ and the proposal that it may be more appropriate to view ONJ as a drug and not only a bisphosphonate-related complication.

Type

Journal article

Journal

Journal of the National Cancer Institute

Publication Date

02/2011

Volume

103

Pages

232 - 240

Addresses

Institute of Musculoskeletal Sciences, University of Oxford, The Botnar Research Centre, Nuffield Orthopaedic Centre, Headington, Oxford, UK. Michael.Pazianas@ndorms.ox.ac.uk

Keywords

Mouth Mucosa, Monocytes, Macrophages, Osteoclasts, Humans, Osteomyelitis, Osteonecrosis, Jaw Diseases, Mevalonic Acid, Diphosphonates, Alendronate, Etidronic Acid, Imidazoles, Pyrroles, Indoles, Vitamin D, Antineoplastic Agents, Antibodies, Monoclonal, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Positron-Emission Tomography, Tomography, X-Ray Computed, Magnetic Resonance Imaging, Radiography, Panoramic, Risk Factors, Signal Transduction, Bone Density Conservation Agents, RANK Ligand, Antibodies, Monoclonal, Humanized